Table 1 Summary of studies and treatment arms included in the primary mixed treatment comparison analysis
N (%) | N (%) | ||
|---|---|---|---|
Total studies | 31 | Total treatment arms | 75 |
Endpoint reported | Placebo | 2 (3) | |
Change from baseline in FEV1 | 28 (90) | FF/VI 92/22 QD | 3 (4) |
Change from baseline in PEF | 18 (58) | FF/VI 184/22 QD | 1 (1) |
Annual rate of exacerbations | 6 (19) | FF 100 QD | 2 (3) |
Change from baseline in AQLQ | 7 (23) | FF 200 QD | 1 (1) |
Mean age reported | 41.74 | FP/SAL 100/50 BID | 8 (11) |
Mean percent male | 40.51 | FP/SAL 250/50 BID | 11 (15) |
Mean baseline FEV1 | 2.30 | FP/SAL 500/50 BID | 5 (7) |
BUD/FORM 320/9 BID | 12 (16) | ||
BUD/FORM 640/18 BID | 1 (1) | ||
BUD/FORM 80/4.5 BID | 2 (3) | ||
BUD 360 BID | 5 (7) | ||
BUD 640 BID | 2 (3) | ||
BUD 360 BID | 1 (1) | ||
BUD 80 BID | 1 (1) | ||
BDP (HFA extra-fine)/FORM 200/12 BID | 2 (3) | ||
FORM 9 BID | 1 (1) | ||
FP 250 BID | 3 (4) | ||
FP 500 BID | 4 (5) | ||
FP 100 BID | 1 (1) | ||
FP 100 BID + Montelukast 10 QD | 3 (4) | ||
FP/FORM 250/10 BID | 1 (1) | ||
MMF/F 200/10 BID | 2 (3) | ||
MMF/F 400/10 BID | 1 (1) |